Found: 6
Select item for more details and to access through your institution.
Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study.
- Published in:
- Clinical Medicine Insights: Oncology, 2022, p. 1, doi. 10.1177/11795549221137135
- By:
- Publication type:
- Article
Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-29706-6
- By:
- Publication type:
- Article
Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 8, p. 2247, doi. 10.3390/jcm11082247
- By:
- Publication type:
- Article
The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer.
- Published in:
- International Journal of Cancer, 2012, v. 130, n. 1, p. 20, doi. 10.1002/ijc.25961
- By:
- Publication type:
- Article
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling Matsumura et al.
- Published in:
- Cancer Science, 2010, v. 101, n. 12, p. 2658, doi. 10.1111/j.1349-7006.2010.01736.x
- By:
- Publication type:
- Article